Lastly, even though KRAS/STK11 mutant tumor have lower PD-L1 expression when compared KRASm/STK11wt, the presence of mutations resulted independent of PD-L1 expression; furthermore, the association of STK11 mutation with worse clinical outcome was also confirmed among PD-L1 positive subgroup of KRAS/STK11 mutant NSCLC patients treated with ICIs [67]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.